Last reviewed · How we verify
Biological: GC3111 vaccine
Biological: GC3111 vaccine is a Biologic drug developed by Green Cross Corporation. It is currently in Phase 1 development. Also known as: GC3111.
At a glance
| Generic name | Biological: GC3111 vaccine |
|---|---|
| Also known as | GC3111 |
| Sponsor | Green Cross Corporation |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biological: GC3111 vaccine CI brief — competitive landscape report
- Biological: GC3111 vaccine updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI
Frequently asked questions about Biological: GC3111 vaccine
What is Biological: GC3111 vaccine?
Biological: GC3111 vaccine is a Biologic drug developed by Green Cross Corporation.
Who makes Biological: GC3111 vaccine?
Biological: GC3111 vaccine is developed by Green Cross Corporation (see full Green Cross Corporation pipeline at /company/green-cross-corporation).
Is Biological: GC3111 vaccine also known as anything else?
Biological: GC3111 vaccine is also known as GC3111.
What development phase is Biological: GC3111 vaccine in?
Biological: GC3111 vaccine is in Phase 1.
Related
- Manufacturer: Green Cross Corporation — full pipeline
- Also known as: GC3111
- Compare: Biological: GC3111 vaccine vs similar drugs
- Pricing: Biological: GC3111 vaccine cost, discount & access